Vaccines

This is an excerpt from Medically Necessary, a health care supply chain newsletter. Subscribe here. The news: A panel advising the Food and Drug Administration recommended approving COVID-19 booster shots only for people over age 65 and people who have a high risk of developing severe COVID-19...

As a new month opens, “reopening” stocks are finding some new life in spite of growing worries about the Delta variant. Shares of stocks tied to the reopening of the economy, including casinos, restaurants, hotels, and airlines, helped lead overnight gains. Overall, Tuesday’s...

More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia reported Wednesday. What Happened: Nearly 1.6 million doses were put out of use in Japan, as per the country’s...

Moderna Inc (NASDAQ: MRNA) shares are reversing course and are higher Tuesday. UK Expands Authorization: The UK drug regulator — the Medicines and Healthcare Products Regulatory Agency — announced Tuesday it has expanded the authorization given to Moderna's...

Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What Happened: Novavax announced Monday it has appointed biopharma industry veteran Jim Kelly as executive vice president, CFO and...

Moderna Inc (NASDAQ: MRNA) announced a double dose of positive tidings Monday, but the stock is still wallowing in the red amid a sell-off seen across vaccine stocks. Moderna Augments Supply Deal With Canada: Cambridge, Massachusetts-based Moderna announced a revised supply agreement...

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Thursday alongside other vaccine maker stocks. Stocks have been trading higher recently as the COVIS-19 delta variant has been spreading throughout the U.S. Inovio Pharmaceuticals was up 13.45% at $9.70 at last check...

The U.S. Food and Drug Administration is expected to authorize on Thursday a third dose of the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna Inc. (NASDAQ: MRNA) COVID-19 vaccines for certain people with weakened immune systems, the New York Times reported. What Happened: The...

Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19...

The sell-off in Moderna, Inc. (NASDAQ: MRNA)'s shares intensified Wednesday amid fears concerning stretched valuation and potential side effects from its mRNA vaccine. Moderna shares closed at a record high of $484.47 on Monday, propelled by optimism concerning its vaccine against the novel...

Novavax, Inc (NASDAQ: NVAX) shares closed 12.24% higher in the regular session on Monday. What Happened: The biotechnology company working on a COVID-19 vaccine saw its shares move 0.74% higher in the after-hours trading. The New York State Common Retirement Fund, the third-largest public pension...

Moderna Inc (NASDAQ: MRNA), a company founded in 2010, is now worth more than the 130-year old Merck & Co., Inc (NYSE: MRK) in terms of market capitalization. What Happened: Moderna’s shares spiked Monday amid a string of positive news including being granted provisional registration...

Moderna Inc (NASDAQ: MRNA) shares are experiencing weakness for a second straight session following the release of its quarterly results. The Moderna Analyst: Oppenheimer analyst Hartaj Singh downgraded Moderna shares from Outperform to Perform. The Moderna Thesis: Moderna exceeded...

Novavax, Inc (NASDAQ: NVAX) shares slipped nearly 10% in the after-hours trading on Thursday. What’s Moving? The biotechnology company’s shares crashed 9.79% to $213.07 in the after-hours session on Thursday after closing 5.54% higher at $236.20. The fall in the shares came after the...

Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Wednesday after the company announced it finalized an advanced purchase agreement with the European Commission for the purchase of up to 200 million doses of its COVID-19 vaccine. Novavax was up 20.50% at $227.73 at last check Wednesday....